Dr. Yuhong Dong and Dr. Jordan Vaughn write at Epoch Health Why Spike Protein Causes Abnormal, Foot-Long Blood Clots, 200 Symptoms.  Excerpts in italics with my bolds.

In this two-part paper, we aim to give an overview on COVID-19 related abnormal blood clots, how they form, how to detect them early, and how they’re being treated

Strange Blood Clots

Since mid-2021, unusual, lengthy blood clots found in the vessels of COVID-19 patients and jab recipients have been reported across the world.  

Where do these strange, fibrous clots come from? How do they form?

Spike Protein: The First Domino Toppled

Blood is a liquid that circulates under pressure through the blood vessels in our whole body, like the water flowing through the house that you then use to shower, do the dishes, and so on.

Following a vascular injury, any blood “leaking out” must rapidly be converted into a gel (a “clot”) to fill in the hole and minimize further blood loss.

Normally, the plasma portion of blood contains a collection of soluble proteins that act together in a series of enzyme activation events that result in the formation of a fibrin clot. This process is protective, as it prevents excessive blood loss following injury.

Unfortunately, the blood clotting mechanism can also lead to unwanted blood clots inside blood vessels (pathologic thrombosis), e.g. heart attack or stroke, both of which are a leading cause of disability and death in the world.

COVID-19’s way of causing abnormal blood clots has spurred many discussions since early 2020.

It appears that the virus’s unique spike protein triggers the cascade via many “non-traditional” pathways.

The spike protein’s direct invasion of the epithelium cells is the first domino toppled.  Subsequent cascade effects finally cause the blood clotting. 

CV Spike Proteins Work in Multiple Ways

The article goes on to discuss the several mechanisms employed by spike proteins to clot blood.

Spike Proteins Impair Epithelium Cells

Spike Proteins Trigger the Clotting Cascade

Spike Proteins Dysregulate RAAS, Worsening the Clotting State

Spike Proteins Directly Disrupt the Clot Dissolving Mechanism

Spike Proteins Form Amyloid-Like Substance

Spike Proteins Inhibit Another Anti-Clot Mechanism

Spike Protein Is the Smoking Gun

There is clinical evidence that the SARS-CoV-2 spike protein has been detected in clots retrieved from COVID-19 patients with acute ischemic stroke and myocardial infarction.

Recent research conducted by cardiologists from the University of Colorado sheds light on the crucial role of spike protein in the pathology of COVID and COVID vaccine-related injuries.

They analyzed seven COVID-19 patients and six mRNA vaccinated patients with myocardial injury and found nearly identical alterations in gene profiling patterns that would predispose them to clotting state, inflammation, and myocardial dysfunction.

In other words, whether the myocarditis was caused by the virus or vaccine, similar
changes were exhibited in the expression of genes responsible for prothrombotic state
in response to spike protein, inflammation, and myocardial dysfunction.

Based on gene analysis, COVID-19 and post-mRNA vaccine injury have a common molecular mechanism.  The altered genes pattern includes down-regulation in ACE2, ACE2/ACE ratio, AGTR1, and ITGA5, and up-regulation in ACE and F3 (tissue factor).

What is more alarming and not reported before is that microvascular thrombosis has been found in post-vaccinated patients, indicating that spike protein itself is able to trigger blood clots in susceptible patients.

Tip of the Iceberg

Based on the causal relation between ChAdOx1-S vaccines (the AstraZeneca adenovirus COVID vaccine) and thrombosis with thrombocytopenia syndrome, the product information for ChAdOx1-S has been updated to include thrombosis with thrombocytopenia syndrome as a very rare side effect.

This has been named as vaccine induced immune thrombotic thrombocytopenia (VITT), due to the fact that in almost every patient in these reports, high levels of antibodies to platelet factor 4 (PF4)–polyanion complexes were identified in their body.

These unusual blood clots in combination with thrombocytopenia were reported predominantly in women aged under 60 years. Accordingly, several European countries restricted the use of adenovirus vaccines in younger age groups.

This risk has been recently systematically analyzed in an international network cohort study from five European countries and the United States, confirming pooled 30 percent increased risk of thrombocytopenia after a first dose of the ChAdOx1-S vaccine, as well as a trend towards an increased risk of venous thrombosis with thrombocytopenia syndrome after Ad26.COV2.S (the Janssen COVID vaccine) compared with BNT162b2 (the Pfizer-BioNTech COVID vaccine).

However this may be only the tip of the iceberg. There are many more events that could be attributed to the clotting issues including sudden death, cardiovascular events, cardiac death, stroke, disabilities, thrombotic events, etc.

Blood vessels are in all our organs. The vessel problems could explain a wide range of symptoms from the dysfunction to mild decline of our brain, heart, lung, and extremities.

Footnote  Why I Boosted with Novavax